Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 5/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8253933 | 0.89 | KDM4E (0.40) | KDM4EALDH1A1HPGDHSD17B10NQO2 | |
| SCHEMBL10164497 | 0.84 | CYP1A2 (0.46) | KDM4EALDH1A1HPGDHSD17B10LCK | |
| SCHEMBL4224849 | 0.82 | KDM4E (0.51) | KDM4EALDH1A1HPGDHSD17B10NQO2 | |
| SCHEMBL10164411 | 0.81 | KDM4E (0.44) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL10164479 | 0.77 | LCK (0.40) | KDM4EALDH1A1HPGDHSD17B10LCK | |
| SCHEMBL10165316 | 0.74 | SMN1; SMN2 (0.53) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL8249377 | 0.72 | KDM4E (0.44) | KDM4EALDH1A1HPGDHSD17B10LCK | |
| SCHEMBL20064823 | 0.71 | KDM4E (0.39) | KDM4EALDH1A1HPGDHSD17B10NQO2 | |
| SCHEMBL20064730 | 0.71 | KDM4E (0.42) | KDM4EALDH1A1HPGDHSD17B10NQO2 | |
| SCHEMBL10164461 | 0.71 | MAPK1 (0.48) | ALDH1A1HPGDHSD17B10LCKSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | KDM4E 2058/4885ALDH1A1 1806/4885HPGD 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.